Why Surface Oncology Is Flying Higher After Hours Today

Regulatory approvals are big wins for biotech companies. It is no different for cancer drug specialist Surface Oncology (NASDAQ: SURF), the shares of which were up nearly 13% in early after-hours trading Tuesday following an important nod from the U.S. Food and Drug Administration (FDA).

After market close, Surface Oncology announced that the regulator granted the company's SRF617 orphan drug designation for the treatment of pancreatic cancer.   

Image source: Getty Images.

Continue reading

Source Fool.com